Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40606 | 0.89 | MAPT (0.58) | MAPTCA12SOS1ALDH1A1TDP1 | |
| SCHEMBL11049170 | 0.86 | MAPT (0.69) | MAPTCA12SOS1ALDH1A1NPSR1 | |
| SCHEMBL9978289 | 0.86 | MAPT (0.69) | MAPTCA12SOS1ALDH1A1NPSR1 | |
| SCHEMBL14935499 | 0.86 | MAPT (0.69) | MAPTCA12SOS1ALDH1A1NPSR1 | |
| SCHEMBL11296000 | 0.84 | MAPT (0.67) | MAPTCA12SOS1ALDH1A1NPSR1 | |
| 2-Nitrobenzaldehyde SCHEMBL5654 | 0.84 | ERN1 (0.66) | MAPTCA12SOS1ALDH1A1TDP1 | |
| SCHEMBL11299049 | 0.84 | MAPT (0.67) | MAPTCA12SOS1ALDH1A1NPSR1 | |
| 2-Nitrobenzaldehyde SCHEMBL29672618 | 0.84 | ERN1 (0.66) | MAPTCA12SOS1ALDH1A1TDP1 | |
| SCHEMBL34722 | 0.82 | MAPT (0.55) | MAPTCA12SOS1ALDH1A1TDP1 | |
| 2-Nitrobenzaldehyde SCHEMBL9323445 | 0.82 | ERN1 (0.63) | MAPTCA12SOS1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| US-20200246471-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | NEKTAR THERAPEUTICS (US) | 2020-08-06 | — | — | US | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-8304168-B2 | Lithographic printing plate precursor and process for producing lithographic printing plate | FUJIFILM CORPORATION (JP) | 2012-11-06 | — | — | US | claimed |
| US-20100075255-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PROCESS FOR PRODUCING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2010-03-25 | — | — | US | claimed |
| EP-1534670-B1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER REC TECH LTD (GB) | 2009-12-02 | — | — | EP | claimed |
| WO-2005000360-A2 | PEG DERIVATIVES HAVING AN AMIDOCARBONATE LINKAGE | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | claimed |
| EP-0700378-B1 | COMPOUNDS WHICH RELEASE NITRIC OXIDE | UNIV CALIFORNIA (US) | 2000-12-20 | — | — | EP | claimed |
| US-5616600-A | Griseolic acid compounds and their use as a phosphodiesterase inhibitor | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0700378-A1 | COMPOUNDS WHICH RELEASE NITRIC OXIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-03-13 | — | — | EP | claimed |
| EP-0700378-A4 | COMPOUNDS WHICH RELEASE NITRIC OXIDE | UNIV CALIFORNIA (US) | 1996-01-22 | — | — | EP | claimed |
| US-5405950-A | N4 -substituted cytidines and process for incorporation into an oligonucleotides | AMOCO CORPORATION (US) | 1995-04-11 | — | — | US | claimed |
| US-5374710-A | Compounds which release nitric oxide upon illumination | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-12-20 | — | — | US | claimed |
| WO-1994027957-A1 | COMPOUNDS WHICH RELEASE NITRIC OXIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-12-08 | — | — | WO | claimed |
| US-4631150-A | Process for the preparation of penems | FARMITALIA CARLO ERBA S.P.A. (IT) | 1986-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246471-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | CD44, PIGO, PGLS | MAPT 267/4885CA12 342/4885SOS1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.